Ligand Lands $2M From Wuxi Biologics

San Diego-based Ligand Pharmaceuticals said on Friday that it will receive $2M in a payment from Wuxi Biologics, as a result of licensing of the exclusive rights to its anti-PD-1 antibody GLS-010 to Arcus Biosciences in North America, Europe, Japan and certain other territories. Ligand says it also is entitled to future milestones and royalties from this antibody.